Boehringer acquires potential drug to treat NASH
The company will develop and commercialize the anti-inflammatory drug phase 1 candidate discovered by Pharmaxis as a potential treatment for nonalcoholic steatohepatitis (NASH)
2015-05-21 Ringier Medical

Login/Register
Supplier Login












Home










